Abstract
Background The heterogeneous phenotype of diabetic nephropathy (DN) from type 2 diabetes complicates appropriate treatment approaches and outcome prediction. Kidney histology helps diagnose DN and predict its outcomes, and an artificial intelligence (AI)- based approach will maximize clinical utility of histopathological evaluation. Herein, we addressed whether AI-based integration of urine proteomics and image features improves DN classification and its outcome prediction, altogether augmenting and advancing pathology practice.
Methods We studied whole slide images (WSIs) of periodic acid-Schiff-stained kidney biopsies from 56 DN patients with associated urinary proteomics data. We identified urinary proteins differentially expressed in patients who developed end-stage kidney disease (ESKD) within two years of biopsy. Extending our previously published human-AI-loop pipeline, six renal sub-compartments were computationally segmented from each WSI. Hand-engineered image features for glomeruli and tubules, and urinary protein measurements, were used as inputs to deep-learning frameworks to predict ESKD outcome. Differential expression was correlated with digital image features using the Spearman rank sum coefficient.
Results A total of 45 urinary proteins were differentially detected in progressors, which was most predictive of ESKD (AUC=0.95), while tubular and glomerular features were less predictive (AUC=0.71 and AUC=0.63, respectively). Accordingly, a correlation map between canonical cell-type proteins, such as epidermal growth factor and secreted phosphoprotein 1, and AI-based image features was obtained, which supports previous pathobiological results. Conclusions: Computational method-based integration of urinary and image biomarkers may improve the pathophysiological understanding of DN progression as well as carry clinical implications in histopathological evaluation.
Significance Statement The complex phenotype of diabetic nephropathy from type 2 diabetes complicates diagnosis and prognosis of patients. Kidney histology may help overcome this difficult situation, particularly if it further suggests molecular profiles. This study describes a method using panoptic segmentation and deep learning to interrogate both urinary proteomics and histomorphometric image features to predict whether patients progress to end-stage kidney disease since biopsy date. A subset of urinary proteomics had the most predictive power in identifying progressors, which could annotate significant tubular and glomerular features related to outcomes. This computational method, which aligns molecular profiles and histology, may improve our understanding of pathophysiological progression of diabetic nephropathy as well as carry clinical implications in histopathological evaluation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Pinaki Sarders work is supported by NIH-NIDDK grant R01 DK114485 R01 DK131189 and R21 DK128668 via the opportunity pool funding mechanism namely via the glue grant mechanism of the NIH-NIDDK Kidney Precision Medicine Project (KPMP) consortium grant U2C DK114886 NIH-OD Human Biomolecular Atlas Project (HuBMAP) consortium Integration Visualization & Engagement (HIVE) project OT2 OD033753 NIH/NCI Coordinating and Data Management Center for Acquired Resistance to Therapy Network U24 CA274159, and start-up funding from University of Florida. Seung Seok Hans work is supported by the SNUH Research Fund (26-2018-0040 26-2022-0040).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human data collection followed protocols approved by the Institutional Review Board at the Seoul National University Hospital (H-1812-159-998).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
All authors have seen and approved the manuscript.
Data Availability
Data & Code Availability Codes for Panoptic Segmentation are available at https://github.com/SarderLab/Watershed_Panoptic_Segmentation Codes for Object and Feature Extraction are available at https://github.com/SarderLab/Object_and_Feature_Extraction Codes for Neural Network prediction of DN progression are available at https://github.com/SarderLab/DN_progression_prediction WSIs, corresponding multi-compartmental segmentations, trained model files and all the corresponding outcomes, as well as confounding data for analyzing the performance our finding are available at https://bit.ly/3MhFYQc. Raw measured proteomics data is available via Supp. Table 7.
https://github.com/SarderLab/Watershed_Panoptic_Segmentation
